Zydus Lifesciences Q4: Net profit marginally down, revenue rises 18%; board recommends dividend for FY25

Zydus’ revenue, however, increased 18% year-on-year (YoY) to ₹6,528 crore as compared to ₹5,533 crore in Q4 FY24.

Its earnings before interest, tax, depreciation, and amortisation (EBITDA) for the quarter under review were at ₹2,126 crore, rising 30.3% from ₹1,630.5 crore reported in the corresponding quarter the preceding year. Its margin improved 32.6% YoY as against 29.5%.

The company said its board has recommended a final dividend of ₹11 per equity share of ₹1 each, subject to approval of the shareholders at the Annual General Meeting scheduled to be held on August 12, 2025.

The drugmaker’s India-branded formulations business posted double-digit growth and outpaced the market growth. Its consumer wellness business also delivered robust double-digit growth aided by strong volume uptake.

The company’s US formulations business continued its upward journey with robust growth driven by volume expansion and new product launches. It clocked revenues of ₹3,130.7 crore, up 24% YoY.

Its international markets business grew in double digits, driven by strong demand-led growth across geographies.

The firm informed that its active pharmaceutical ingredients (API) business revenue was down 10% at ₹129 crore.

“We are happy to conclude FY 2025 on a strong note, with all our businesses surpassing our growth expectations. The commercial success of our extensive product portfolio combined with operating leverage has significantly bolstered profitability and financial health. We made meaningful progress in our differentiated pipeline and added new capabilities to ensure sustainable growth," said Dr Sharvil Patel, Managing Director of Zydus Lifesciences.

"We look forward to continued execution success and deepening strategic partnerships to drive long-term growth. Our commitment to maintaining the highest quality standards across our operations remains unwavering,” Patel further said.

Following the earnings announcement, shares of Zydus were trading 2.98% lower at ₹884.1 apiece on the National Stock Exchange.